Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 3/20 | 0.56 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.54 |
| ▸ | APOB | P04114 | 9/20 | 0.54 |
| ▸ | MTTP | P55157 | 8/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.49 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6801792 | 0.89 | TP53 (0.56) | P2RX1APOBMTTPMAPTLMNA | |
| SCHEMBL6805325 | 0.83 | KCNMA1 (0.51) | P2RX1KCNMA1APOBMTTPMAPT | |
| SCHEMBL6805317 | 0.83 | KCNMA1 (0.51) | P2RX1KCNMA1APOBMTTPMAPT | |
| SCHEMBL6794433 | 0.83 | ABCG2 (0.70) | P2RX1APOBMTTPMAPTABCG2 | |
| SCHEMBL14031525 | 0.81 | KCNMA1 (0.66) | P2RX1KCNMA1APOBMTTPMAPT | |
| SCHEMBL4347085 | 0.79 | CA12 (0.61) | P2RX1KCNMA1MAPTLMNATRPV1 | |
| SCHEMBL6794747 | 0.79 | PTGS1 (0.60) | P2RX1APOBMTTPMAPTLMNA | |
| SCHEMBL6804166 | 0.79 | SMO (0.61) | P2RX1KCNMA1APOBMTTPLMNA | |
| SCHEMBL6638787 | 0.78 | LMNA (0.55) | P2RX1KCNMA1MAPTLMNATRPV1 | |
| SCHEMBL6798429 | 0.78 | SMO (0.57) | P2RX1KCNMA1APOBMTTPMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | P2RX1 3450/4885KCNMA1 1726/4885APOB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.